Screener
Ligand Pharmaceuticals LGND Ohtuvayre inventors — Financial Royalty Assets, Net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsNet.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Qarziba | $101,303 | $(468) | $100,835 | $118,593 | $(498) | $118,095 |
| Agenus Bot/Bal | 40,815 | (408) | 40,407 | 40,815 | (408) | 40,407 |
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's ohtuvayre inventors — financial royalty assets, net?
- Ligand Pharmaceuticals (LGND) reported ohtuvayre inventors — financial royalty assets, net of $19.78M in Q2 2026.
- What does ohtuvayre inventors — financial royalty assets, net mean?
- This metric represents the net book value of royalty assets associated with the Ohtuvayre product line after accounting for accumulated amortization and valuation allowances. It serves as a measure of the current carrying value of the asset on the balance sheet, representing the expected future economic benefits. Investors track this to evaluate the remaining value of the company's intellectual property and its potential for future cash generation.
Ask your AI about Ligand Pharmaceuticals's ohtuvayre inventors — financial royalty assets, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude